Author

Shuai Mao

University of MichiganORCID 0000-0003-0856-8007Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Chengyi LiiD· 2 shared Duxin SuniD· 2 shared Hanning Wen· 2 shared Mahamadou Djibo· 2 shared Alejandro BalsaiD· 1 shared Bo WeniD· 1 shared Fang KeiD· 1 shared Hongxiang HuiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Chengyi LiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologyACS NanoPeer-reviewedFeb 13, 2025

SARS-CoV-2 B Epitope-Guided Neoantigen NanoVaccines Enhance Tumor-Specific CD4/CD8 T Cell Immunity Through B Cell Antigen Presentation

Chengyi Li, Fang Ke, Shuai Mao…·Duxin Sun

This study develops a neoantigen vaccine using SARS-CoV-2 B cell epitopes to enhance CD4/CD8 T cell immunity through B cell antigen presentation, showing improved efficacy in multiple cancer models.

10 citations

humanproteomics

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintFeb 14, 2024

Dual Targeting of STING and PI3Kγ Eliminates Regulatory B Cells to Overcome STING Resistance for Pancreatic Cancer Immunotherapy

Chengyi Li, Shuai Mao, Hongyi Zhao…·Duxin Sun

This paper develops a dual-targeting compound that eliminates regulatory B cells and overcomes STING resistance in pancreatic cancer, improving immunotherapy outcomes.

DOI 10.1101/2024.02.14.580378

mouseproteomics

𝕏 PostBluesky